실시간
Endpoints NewsLilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drugEndpoints NewsTrodelvy misses in lung cancer, but Gilead and Merck have an HIV successFierceBiotechADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal programFierceBiotechLilly moves deeper into Alzheimer’s research with AlzeCure licensing dealFierceBiotechCancer biotech Parabilis ups IPO plans to potentially record-setting $637MEndpoints NewsEndpoints Women in Biopharma: Nominate for 2026Lonza NewsAmMax Bio licenses ADC technology from Lonza - The Pharma LetterFDA News ReleasesFDA Expands Sunscreen Options for the First Time in 20 YearsEndpoints NewsPharma and biotech salaries: Top-paying companies of 2025FierceBiotechRoche sticks with €600M diagnostics investment in Germany but warns of future risk10x Genomics Blog10x Genomics (TXG) Expands Capabilities with Proteintech Genomics Acquisition - GuruFocusFierceBiotechCeQur nabs $100M series E to fuel insulin patch commercialization
eLife 2026년 1월 27일

Microglia replacement by ER-Hoxb8 conditionally immortalized macrophages provides insight into Aicardi–Goutières syndrome neuropathology

Microglia replacement by ER-Hoxb8 conditionally immortalized macrophages provides insight into Aicardi–Goutières syndrome neuropathology

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.